Abstract
Objectives. Since subjects may have been diagnosed before cohort entry, analysis of late HIV diagnosis (LD) is usually restricted to the newly diagnosed. We estimate the magnitude and risk factors of LD in a cohort of seroprevalent individuals by imputing seroconversion dates. Methods. Multicenter cohort of HIV-positive subjects who were treatment naive at entry, in Spain, 2004–2008. Multiple-imputation techniques were used. Subjects with times to HIV diagnosis longer than 4.19 years were considered LD. Results. Median time to HIV diagnosis was 2.8 years in the whole cohort of 3,667 subjects. Factors significantly associated with LD were: male sex; Sub-Saharan African, Latin-American origin compared to Spaniards; and older age. In 2,928 newly diagnosed subjects, median time to diagnosis was 3.3 years, and LD was more common in injecting drug users. Conclusions. Estimates of the magnitude and risk factors of LD for the whole cohort differ from those obtained for new HIV diagnoses.
1. Introduction
The majority of clinical cohorts of HIV-infected people are made up of seroprevalent subjects whose dates of seroconversion are unknown [1–3]. Seroprevalent subjects have been used to quantify the magnitude and risk factors of late diagnosis of HIV infection, an important public health problem which, by definition, cannot be studied in seroconverter cohorts [4, 5]. Although there are multiple definitions of late diagnosis based on different biological markers [4, 6–8], most of them are based on the patient's CD4 lymphocyte count close to the date of HIV diagnosis. For some persons, HIV may have been diagnosed before their inclusion in a clinical cohort; therefore, no CD4 counts close to HIV diagnosis are usually available. Consequently, these people are ignored, and estimates are obtained only from those with available CD4 counts—largely the new HIV diagnoses—rather than from the whole cohort. Most clinical cohorts include newly diagnosed people as well as people who have been diagnosed in the past, but the latter group is rendered invisible. The use of multiple imputation techniques to estimate the time between HIV seroconversion and HIV diagnosis could overcome the aforementioned problem. These techniques, which so far have not been applied to study late HIV diagnosis, are based on the correlation between certain biological markers like CD4 lymphocytes and the duration of infection [9–11].
The magnitude of late HIV diagnoses in the subgroup of new HIV diagnoses in cohorts from industrialized countries ranges from 18% to 39% [4, 5, 12–14]. For these cohorts, the proportion of subjects who are new HIV diagnoses—and therefore can be analyzed—ranges from 4% to 73% [4, 5, 12–15]. In Spain, considering late diagnosis as subjects with a CD4 lymphocyte count of <200 cells/mm3 or an AIDS-defining disease in the first year after HIV diagnosis, we reported 37% of late diagnosis in 2004–06 in the 68% of subjects who could be evaluated because they were newly diagnosed at inclusion in the cohort [16]. Risk of late diagnosis increased with age, was higher in men than in women, and, contrary to previous publications [12, 17, 18], was higher in heterosexuals and injection drug users (IDUs) compared to men who have sex with men (MSM). We hypothesized that this unexpected finding may reflect that the new diagnoses represent a different population than the old ones, which could not be evaluated for late diagnosis analyses [16]. To test this hypothesis, we estimated the magnitude and risk factors of late HIV diagnosis, in all cohort members and separately in those newly diagnosed, in a multicenter cohort of seroprevalent subjects in Spain for whom we have imputed their HIV seroconversion dates.
2. Methods
CoRIS is an open, multicenter, and prospective cohort of adult patients with confirmed HIV infection who are naive to antiretroviral treatment (ART) at the first visit to any of the CoRIS centers and who agree to participate in the study by signing an informed consent form. A complete description has been published elsewhere [19]. Briefly, CoRIS collects a minimum dataset which is subject to internal and external quality controls. Between January 2004 and October 2008, 4,057 subjects were recruited from 27 participating centers where the percentage of CD4 lymphocytes (hereinafter referred to as “CD4%”) was measured. A total of 231 subjects were excluded because they had recently been recruited, and no CD4% results were available, and 159 were excluded because their first CD4% values were recorded after ART initiation. Accordingly, 3,667 patients were available for analysis.
Subjects were classified as late diagnosis (LD) when the diagnosis of HIV infection was made more than 4.19 years after seroconversion. This cut-off point was chosen because, in a previous publication [20], it was estimated that this was the time elapsed from seroconversion to reaching a CD4 threshold of <350. In turn, this CD4 lymphocyte threshold is used in the new definition of late presentation recommended by the European Late Presenter Consensus Working Group [6].
A multiple imputation technique was used to estimate the date of seroconversion of all CoRIS subjects, based on the model for progression of infection described by Muñoz et al. [10], which has been used in Spain [11]. These authors use parametric survival models based on the Weibull distribution to estimate the time elapsed between the date of HIV seroconversion and the date of first CD4% in the absence of ART, on the basis of that first CD4%. Their paper describes the model's parameter for each of the five thresholds in which CD4% is categorized.
This model and its coefficients allow us to know the probability that the date of seroconversion falls before a given date, conditioned by the fact that it must be between the date when the subject started being at risk for HIV infection and the date of HIV diagnosis. From this model equation, we can estimate (impute) the timespan between the date of seroconversion and the date of HIV diagnosis when the following information is made available for each subject: (a) date when the subject started being at risk for HIV infection, (b) date of HIV diagnosis, and (c) the value of CD4% and the date it was measured.
We used the following imputation process: (1) for each individual, a random number was drawn from a Weibull distribution with the parameters corresponding to his/her CD4% threshold, which was considered a random estimate of the timespan between the date of seroconversion and the date of first CD4% (t). This made it possible to calculate the timespan between the date of seroconversion and the date of HIV diagnosis (“time to HIV diagnosis”, t1), and the date of seroconversion as the difference between the date of first CD4% minus time t. Subjects whose time t1 was longer than 4.19 years were considered late diagnoses. (2) The preceding process was replicated 20 times. Twenty different databases were generated with the information obtained in each replication. (3) The subsequent analyses were made by combining the results obtained when analyzing these 20 databases separately.
We also present the results obtained using the definition that classified subjects as delayed diagnosis (DD) when they had a CD4 lymphocyte count of <350 cells/mm3 in the first year after HIV diagnosis or an AIDS-defining disease in the first three months after HIV diagnosis. Thus, this definition only permitted the evaluation of subjects for whom that information was available, that is, the new HIV diagnoses.
We assumed that the date when a subject started being at risk for HIV infection was the beginning of the epidemic in Spain, 1 January 1980, except in (a) patients infected by the sexual route or by injecting drug use who were born after 1 January 1965; for these subjects, we used the date of their 15th birthday, and (b) patients in the remaining transmission categories who were born after 1 January 1980, for whom we used their date of birth.
We present a descriptive analysis of the characteristics of subjects included in the analysis, as well as their time to HIV diagnosis. We used an analysis of variance for the comparison of means, to compare the time to HIV diagnosis according to patient characteristics.
To evaluate the factors independently associated with late diagnosis, we used a multivariate logistic regression model. In this model, robust methods were used to estimate the confidence intervals, assuming correlation among subjects recruited in each center and independence between subjects in different centers [21].
The analyses were performed using R version 2.13 [22] and Stata 11.
3. Results
Of the 3,667 patients included in this analysis, most were men (77.8%), were infected by sexual transmission (43.1% MSM and 37.5% heterosexual), and were Spanish nationals (68.5%); 15.8% had been infected through injecting drug use. The mean age at HIV diagnosis was 34.8 years (SD = 10.2) and the median follow-up time was 1.38 years. At cohort entry, 442 patients (12%) had been diagnosed with AIDS, another 191 (5.2%) developed AIDS, and 86 persons (2.3%) died during followup.
3.1. Description of Time from Imputed Seroconversion to HIV Diagnosis
3.1.1. Results for All Subjects Included in the Cohort (n = 3667)
The distribution of the dates of HIV diagnosis and the mean imputed seroconversion date per individual can be seen in Figure 1. The shape of the figure is similar in both cases, but with a shift over time. The median date of HIV diagnosis was October 2005 (IQR: June 2004–February 2007) while the median date of seroconversion was February 2002 (IQR: May 1999–May 2004).
Figure 1.
Distribution of date of seroconversion and date of HIV diagnosis.
Table 1 shows the distribution of years elapsed between the mean imputed date of seroconversion and the date of HIV diagnosis. Overall, the median time to HIV diagnosis was 2.8 years (IQR: 1.2–5.2).
Table 1.
Years between imputed date of seroconversion and date of HIV diagnosis in the whole cohort (n = 3667).
| Years between imputed date of seroconversion and date of HIV diagnosis | ||||
|---|---|---|---|---|
| N | Median (P25–P75) | Mean | P | |
| Sex | <0.001 | |||
| Men | 2854 | 2.90 (1.24–5.40) | 3.66 | |
| Women | 813 | 2.32 (0.98–4.60) | 3.15 | |
|
| ||||
| Age at HIV diagnosis | <0.001 | |||
| Up to 20 | 158 | 1.31 (0.49–2.55) | 1.66 | |
| 21–30 | 1239 | 2.11 (0.86–4.36) | 2.93 | |
| 31–40 | 1361 | 2.99 (1.32–5.56) | 3.78 | |
| 41–50 | 599 | 3.67 (1.70–6.05) | 4.25 | |
| 51–60 | 219 | 4.16 (2.18–6.44) | 4.59 | |
| Over 60 | 74 | 4.27 (2.22–6.42) | 4.57 | |
| Not available | 17 | 3.66 (2.04–5.57) | 4.11 | — |
|
| ||||
| Transmission category | <0.001 | |||
| Injection drug user | 578 | 1.82 (0.59–4.40) | 2.87 | |
| Men who have sex with men | 1581 | 2.73 (1.25–5.17) | 3.57 | |
| Heterosexual risk exposure | 1376 | 3.08 (1.38–5.53) | 3.76 | |
| Other (vertical, transfusions, tattoos, etc.) | 58 | 3.03 (1.33–5.48) | 3.63 | |
| Don't know/No answer | 74 | 3.81 (1.83–6.10) | 4.28 | |
|
| ||||
| Educational level | 0.790 | |||
| No education or less than primary | 257 | 2.88 (1.07–5.20) | 3.46 | |
| Primary | 1214 | 2.68 (1.09–5.20) | 3.49 | |
| Secondary completed | 1011 | 2.79 (1.22–5.25) | 3.57 | |
| University completed | 524 | 2.84 (1.29–5.33) | 3.66 | |
| Not available | 661 | 2.75 (1.19–5.20) | 3.54 | — |
|
| ||||
| Country of origin | 0.011 | |||
| Spain | 2512 | 2.57 (1.07–5.06) | 3.42 | |
| Western Europe | 114 | 2.96 (1.23–5.40) | 3.74 | |
| Eastern Europe and Russia | 72 | 2.97 (1.46–5.16) | 3.58 | |
| Sub-Saharan Africa | 246 | 3.54 (1.68–5.88) | 4.04 | |
| North Africa | 58 | 3.89 (1.77–6.35) | 4.51 | |
| Latin America | 631 | 3.04 (1.36–5.45) | 3.71 | |
| Other/not available | 34 | 2.84 (1.46–5.25) | 3.77 | |
|
| ||||
| AIDS | <0.001 | |||
| Yes | 633 | 4.13 (2.01–6.19) | 4.32 | |
| No | 3034 | 2.49 (1.09–4.90) | 3.38 | |
|
| ||||
| Death | 0.081 | |||
| Yes | 86 | 4.08 (1.84–6.12) | 4.25 | |
| No | 3581 | 2.73 (1.16–5.21) | 3.53 | |
|
| ||||
| Total | 3667 | 2.76 (1.17–5.24) | 3.54 | |
Time to HIV diagnosis was longer in men, in persons with heterosexual or “other” routes of transmission (vertical, transfusions, tattoos,…), and, in those from countries other than Spain, it also increased with age at HIV diagnosis and was longer in patients who developed AIDS and in those who died.
Table 2 shows the distribution of late diagnosis according to the sociodemographic characteristics of the subjects and the odds ratio based on the multivariate analysis. Factors independently associated with late diagnosis in the multivariate analysis were male gender, place of origin Sub-Saharan Africa or Latin America, and older age at HIV diagnosis. Subjects with heterosexual transmission had a higher frequency of late diagnoses than MSM although that higher frequency did not attain statistical significance.
Table 2.
Factors associated with late diagnosis (time to HIV diagnosis over 4.19 years).
| Whole cohort (N = 3667) | New HIV diagnoses (N = 2928) | |||||||
|---|---|---|---|---|---|---|---|---|
| LD*/Total | % | Adjusted OR (95% CI) | P | LD*/Total | % | Adjusted OR (95% CI) | P | |
| Sex | ||||||||
| Men | 1018/2854 | 36 | 1.67 (1.27–2.21) | <0.001 | 936/2287 | 41 | 1.77 (1.30–2.40) | <0.001 |
| Women | 233/813 | 29 | 1 | 211/641 | 33 | 1 | ||
|
| ||||||||
| Age at HIV diagnosis | <0.001 | <0.001 | ||||||
| Up to 30 | 337/1397 | 24 | 1 | 296/964 | 31 | 1 | ||
| 31–40 | 498/1361 | 37 | 1.79 (1.46–2.19) | <0.001 | 459/1133 | 41 | 1.49 (1.19–1.87) | <0.001 |
| Over 41 | 408/892 | 46 | 2.64 (2.10–3.30) | <0.001 | 392/830 | 47 | 1.95 (1.56–2.45) | <0.001 |
| Not available | 7/17 | 42 | 1.99 (0.61–6.54) | 0.256 | 1/1 | — | — | 0.808 |
|
| ||||||||
| Transmission category | 0.055 | 0.043 | ||||||
| Injection drug user | 154/578 | 27 | 0.83 (0.62–1.09) | 0.176 | 136/296 | 46 | 1.60 (1.10–2.32) | 0.014 |
| Men who have sex with men | 526/1581 | 33 | 1 | 479/1339 | 36 | 1 | ||
| Heterosexual risk exposure | 516/1376 | 37 | 1.26 (0.98–1.62) | 0.069 | 483/1187 | 41 | 1.39 (1.06–1.82) | 0.016 |
| Other (vertical, transfusions, tattoos, etc.) | 21/58 | 37 | 1.08 (0.56–2.09) | 0.820 | 20/46 | 44 | 1.36 (0.68–2.72) | 0.385 |
| Don't know/No answer | 34/74 | 45 | 1.47 (0.77–2.79) | 0.241 | 30/60 | 50 | 1.70 (0.89–3.21) | 0.105 |
|
| ||||||||
| Country of origin | 0.004 | 0.065 | ||||||
| Spain | 812/2512 | 32 | 1 | 743/1958 | 38 | 1 | ||
| Western Europe | 41/114 | 36 | 1.14 (0.68–1.93) | 0.615 | 34/82 | 41 | 1.11 (0.59–2.09) | 0.744 |
| Eastern Europe and Russia | 25/72 | 35 | 1.48 (0.77–2.86) | 0.243 | 23/64 | 37 | 1.13 (0.56–2.29) | 0.731 |
| Sub-Saharan Africa | 104/246 | 42 | 1.75 (1.20–2.56) | 0.004 | 95/215 | 44 | 1.54 (1.04–2.29) | 0.032 |
| North Africa | 27/58 | 47 | 1.75 (0.85–3.59) | 0.129 | 27/56 | 49 | 1.49 (0.70–3.14) | 0.297 |
| Latin America | 231/631 | 37 | 1.38 (1.09–1.74) | 0.008 | 214/522 | 41 | 1.38 (1.08–1.75) | 0.009 |
| Other/not available | 11/34 | 34 | 0.96 (0.39–2.34) | 0.925 | 11/31 | 36 | 0.92 (0.39–2.18) | 0.846 |
|
| ||||||||
| Total | 1251/3667 | 34 | 1147/2928 | 39 | ||||
*LD.: Late diagnosis (patients with time to HIV diagnosis over 4.19 years).
3.1.2. Results in the Subgroup of New HIV Diagnoses (n = 2928)
In this subgroup of new HIV diagnoses (n = 2,928), the median time to HIV diagnosis was 3.3 years (IQR: 1.6–5.7) (Table 3), longer than the median of 2.8 years estimated for the whole cohort.
Table 3.
Years between the imputed date of seroconversion and the date of HIV diagnosis. Results in the subcohort of new diagnoses (n = 2928).
| Years between imputed date of seroconversion and date of HIV diagnosis | |||||
|---|---|---|---|---|---|
| N | % DD* | Median (P25–P75) | Mean | P | |
| Sex | <0.001 | ||||
| Men | 2287 | 51.8 | 3.42 (1.65–5.83) | 4.07 | |
| Women | 641 | 50.2 | 2.77 (1.32–5.04) | 3.51 | |
|
| |||||
| Age at HIV diagnosis | <0.001 | ||||
| Up to 20 | 93 | 33.3 | 1.94 (1.08–3.05) | 2.15 | |
| 21–30 | 871 | 39.6 | 2.76 (1.33–5.01) | 3.46 | |
| 31–40 | 1133 | 52.0 | 3.36 (1.62–5.89) | 4.09 | |
| 41–50 | 549 | 61.9 | 3.83 (1.87–6.18) | 4.38 | |
| 51–60 | 209 | 69.9 | 4.22 (2.25–6.42) | 4.60 | |
| Over 60 | 72 | 75.0 | 4.37 (2.29–6.47) | 4.63 | |
| Not available | 1 | 100.0 | 5.25 (5.25–5.25) | 5.25 | — |
|
| |||||
| Transmission category | 0.111 | ||||
| Injection drug user | 296 | 66.6 | 3.86 (1.93–6.11) | 4.34 | |
| Men who have sex with men | 1339 | 41.3 | 2.97 (1.42–5.43) | 3.77 | |
| Heterosexual risk exposure | 1187 | 58.0 | 3.39 (1.62–5.79) | 4.00 | |
| Other (vertical, transfusions, tattoos, etc.) | 46 | 63.0 | 3.71 (2.02–5.94) | 4.18 | |
| Don't know/No answer | 60 | 63.3 | 4.18 (2.12–6.44) | 4.57 | |
|
| |||||
| Educational level | 0.640 | ||||
| No education or less than primary | 187 | 63.1 | 3.62 (1.77–5.85) | 4.06 | |
| Primary | 928 | 57.0 | 3.40 (1.62–5.82) | 4.05 | |
| Secondary completed | 853 | 46.0 | 3.13 (1.48–5.57) | 3.85 | |
| University completed | 443 | 41.3 | 3.07 (1.48–5.55) | 3.85 | |
| Not available | 517 | 54.9 | 3.30 (1.61–5.61) | 3.96 | — |
|
| |||||
| Country of origin | 0.410 | ||||
| Spain | 1958 | 49.4 | 3.14 (1.49–5.58) | 3.87 | |
| Western Europe | 82 | 50.0 | 3.47 (1.77–5.80) | 4.19 | |
| Eastern Europe and Russia | 64 | 51.6 | 3.15 (1.59–5.33) | 3.74 | |
| Sub-Saharan Africa | 215 | 61.9 | 3.73 (1.82–6.05) | 4.21 | |
| North Africa | 56 | 60.7 | 4.09 (1.88–6.49) | 4.62 | |
| Latin America | 522 | 54.8 | 3.43 (1.70–5.81) | 4.04 | |
| Other/not available | 31 | 38.7 | 3.09 (1.52–5.73) | 3.97 | |
|
| |||||
| All | 2928 | 51.4 | 3.26 (1.56–5.68) | 3.94 | |
*DD: Delayed diagnosis (patients with CD4 count <350 cells/mm3 in the first year after HIV diagnosis or with AIDS-defining disease in the the first three months after HIV diagnosis).
These differences can partly be explained by the fact that the 739 subjects excluded from the analyses were significantly different (P < 0.05) from the 2,928 who were included; in the following ways, they were younger at diagnosis (mean age 30 versus 36 years) and at seroconversion (mean age 28 versus 32 years); they were more frequently IDUs (38.2% versus 10.1%); they were more often of Spanish origin (75.0% versus 66.9%).
Table 2 shows the distribution of late diagnosis and the results of the multivariate analysis in this subcohort. Unlike what was seen in the whole cohort of 3,667 subjects, IDUs had a higher frequency of late diagnoses compared with MSM. Subjects with heterosexual transmission also had a significantly higher frequency of late diagnoses than MSM.
With regard to sex, age of diagnosis, and country of origin, the results were similar to those for the whole cohort.
Table 3 shows the estimated time to HIV diagnosis in this group and the percentage of delayed diagnoses according to the definition DD. For each of the sociodemographic characteristics studied in the subgroup of 2,928 new HIV diagnoses, we observed high consistency, except in women, between time from imputed seroconversion date to HIV diagnosis and frequency of delayed diagnoses (DD).
4. Discussion
This study illustrates the application of a multiple imputation method to estimate the date of HIV seroconversion in a cohort of seroprevalent patients who are not all newly diagnosed with HIV at entry. We defined as late diagnosis the subjects with times to HIV diagnosis longer than 4.19 years. The advantage of this definition is that it allows estimation of late diagnosis in the whole cohort and not just in patients with CD4 markers close to the time of HIV diagnosis.
Half of the cohort members were not diagnosed with HIV until 2.8 years after becoming infected, and one fourth were not diagnosed until 5.2 years after infection. Based on the multivariate analysis, the time between the imputed date of HIV seroconversion and HIV diagnosis was longer in men, increased with age, and was longer in persons from Sub-Saharan Africa and Latin America compared to Spaniards. In contrast, half of the new HIV diagnoses at entry into the cohort were not diagnosed until 3.3 years after their imputed HIV seroconversion date, and diagnostic delay was more common in IDUs.
By imputing the date of seroconversion, we have shown that the magnitude of late diagnosis in the whole cohort was smaller than in the subgroup of new diagnoses (34% versus 39%). In addition, we found differences not only in the magnitude of late diagnosis but also in the associated risk factors. These differences reflect the important changes in HIV epidemiology, and probably in HIV testing practices as well, that have taken place in Spain in the last decade: a major reduction in the number of IDUs who were exposed to frequent HIV testing opportunities, together with an increase in sexually acquired infections which continues to require more active HIV testing approaches. As CoRIS is not population based, these conclusions cannot be extrapolated to the whole HIV-positive population in Spain.
Our group had already evaluated late diagnosis in the cohort, but limited to those patients with an HIV diagnosis close to the time of their inclusion in the cohort [16]. We had observed a very high prevalence of late diagnoses in IDUs, a result that differed from other studies carried out in Spain which described very high HIV testing uptake in IDUs [12, 17, 18]. Here, by imputing the date of seroconversion, which allows study of the whole cohort, we no longer see a higher frequency of late diagnoses in IDUs although this pattern continues to be seen in the subgroup of new diagnoses. What this reflects is that IDUs diagnosed with HIV before cohort entry—in drug attention centers—were excluded from the analyses. Together with a marked decline in the number of IDUs among new HIV diagnoses in Spain, the analyses of late HIV diagnosis within the surveillance system have also identified a higher frequency of late diagnosis among IDUs [23]. Consistent with previous publications from Spain and other countries [12, 13, 16, 17, 23], late diagnosis is higher in men, in migrants from non-Western countries, and increases with age.
The results of this study are also important for comparison purposes as the proportion of new HIV diagnoses in a cohort may vary between cohorts and within the same cohort over time. For example, cohorts may increase the number of recruiting sites, or HIV incidence may change in a given group. In this work, we highlight the fact that new HIV diagnoses do not represent the whole cohort and that their relative contribution needs to be taken into account when comparing different cohorts or when interpreting trends over time.
Our results are based on imputing the date of seroconversion by using the first available CD4 percentage from each patient while off treatment. Other authors have observed that this estimate can be improved by using the evolution of various CD4 measurements [24, 25]. We also performed this imputation process for each measurement of CD4 percentage and estimated the date of seroconversion as the median date of seroconversion estimated by the imputation for each value of CD4. No differences were found with this analysis; the median date of seroconversion was 1 July 2002. This may be because the median number of CD4 measurements in persons off treatment was only two, since most people start treatment soon after entry.
We also conducted several sensitivity analyses using different assumptions about the date of initial risk, and the results were similar.
To evaluate the influence of the distribution model initially selected to impute the date of seroconversion [10], we analyzed the data based on Weibull models with different parameters which, in some cases, permitted a subject to have been infected for 30 years at the time of CD4 measurement. The results obtained did not differ substantially from those presented.
Time to HIV diagnosis and delayed diagnosis (DD) was not highly consistent in women. Some studies have shown that, after seroconversion, women take longer than men to reach the same CD4 level [20, 26]. Lodi et al. estimate these differences at between 6 and 12 months [20]. We conducted an analysis considering for women a Weibull distribution with the same shape parameter, but with a median of 9 months longer than for men. In this simulation, differences between men and women in time to diagnosis and in the percentage of late diagnosis disappear.
In conclusion, estimates of the magnitude and risk factors of late HIV diagnoses for an entire cohort may differ from those obtained for new HIV diagnoses, a finding that highlights the need to both improve and expand HIV testing practices in our setting.
Funding
The RIS cohort (CoRIS) is funded by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (ISCIII-RETIC RD06/006).
Conflict of Interests
The authors declared that there is no conflict of interests.
Acknowledgments
The authors acknowledge that this study would not have been possible without the collaboration of all the patients, physicians, nurses, and data managers who have taken part in the project. They want to thank Dr. P. Alcamí for his help in immunological interpretation. CoRIS members belong to Cohorte de la Red de Investigación en Sida, Spain.
Appendix
Centers and Investigators Participatingin CoRIS
1. Coordinating Committee —
Juan Berenguer, Julia del Amo, Federico García, Félix Gutiérrez, Pablo Labarga, Santiago Moreno y María Ángeles Muñoz.
2. Field Work, Data Management and Analysis —
Ana María Caro-Murillo, Paz Sobrino Vegas, Santiago Pérez-Cachafeiro, Victoria Hernando Sebastián, Belén Alejos Ferreras, Débora Álvarez, Susana Monge, Inma Jarrín, Mónica Trastoy.
3. BioBanco —
M Ángeles Muñoz-Fernández, Isabel García-Merino, Coral Gómez Rico, Jorge Gallego de la Fuente y Almudena García Torre.
4. Participating Centers —
Hospital General Universitario de Alicante (Alicante) —
Joaquín Portilla Sogorb, Esperanza Merino de Lucas, Sergio Reus Bañuls, Vicente Boix Martínez, Livia Giner Oncina, Carmen Gadea Pastor, Irene Portilla Tamarit, Patricia Arcaina Toledo.
Hospital Universitario de Canarias (Santa Cruz de Tenerife) —
Juan Luis Gómez Sirvent, Patricia Rodríguez Fortúnez, María Remedios Alemán Valls, María del Mar Alonso Socas, Ana María López Lirola, María Inmaculada Hernández Hernández, Felicitas Díaz-Flores.
Hospital Carlos III (Madrid) —
Vicente Soriano, Pablo Labarga, Pablo Barreiro, Carol Castañares, Pablo Rivas, Andrés Ruiz, Francisco Blanco, Pilar García, Mercedes de Diego.
Hospital Universitario Central de Asturias (Oviedo) —
Victor Asensi, Eulalia Valle, José Antonio Cartón.
Hospital Clinic (Barcelona) —
José M. Miró, María López-Dieguez, Christian Manzardo, Laura Zamora, Iñaki Pérez, Mª Teresa García, Carmen Ligero, José Luis Blanco, Felipe García-Alcaide, Esteban Martínez, Josep Mallolas, José M. Gatell.
Hospital Doce de Octubre (Madrid) —
Rafael Rubio, Federico Pulido, Silvana Fiorante, Jara Llenas, Violeta Rodríguez, Mariano Matarranz.
Hospital Donostia (San Sebastián) —
José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Mª Jesús Bustinduy, Harkaitz Azkune Galparsoro.
Hospital General Universitario de Elche (Elche) —
Félix Gutiérrez, Mar Masiá, José Manuel Ramos, Sergio Padilla, Andrés Navarro, Fernando Montolio, Yolanda Peral, Catalina Robledano García.
Hospital Germans Trías i Pujol (Badalona) —
Bonaventura Clotet, Cristina Tural, Lidia Ruiz, Cristina Miranda, Roberto Muga, Jordi Tor, Arantza Sanvisens.
Hospital Gregorio Marañón (Madrid) —
Juan Berenguer, Juan Carlos López Bernaldo de Quirós, Pilar Miralles, Jaime Cosín Ochaíta, Matilde Sánchez Conde, Isabel Gutiérrez Cuellar, Margarita Ramírez Schacke, Belén Padilla Ortega, Paloma Gijón Vidaurreta.
Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili (Tarragona) —
Francesc Vidal, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Joan-Josep Sirvent, Alba Aguilar, Antoni Soriano.
Hospital Universitario La Fe (Valencia) —
José López Aldeguer, Marino Blanes Juliá, José Lacruz Rodrigo, Miguel Salavert, Marta Montero, Eva Calabuig, Sandra Cuéllar.
Hospital Universitário La Paz (Madrid) —
Juan González García, Ignacio Bernardino de la Serna, José María Peña Sánchez de Rivera, Marta Mora Rillo, José Ramón Arribas López, María Luisa Montes Ramírez, José Francisco Pascual Pareja, Blanca Arribas, Juan Miguel Castro, Fco Javier Zamora Vargas, Ignacio Pérez Valero.
Hospital de la Princesa (Madrid) —
Ignacio de los Santos, Jesús Sanz Sanz, Johana Rodríguez, Ana Salas Aparicio, Cristina Sarriá Cepeda.
Hospital San Pedro-CIBIR (Logroño) —
José Antonio Oteo, José Ramón Blanco, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez.
Hospital San Pedro II (Logroño) —
Javier Pinilla Moraza.
Hospital Universitario Mutua de Terrassa (Terrassa) —
David Dalmau, Angels Jaén Manzanera, Mireia Cairó Llobell, Daniel Irigoyen Puig, Laura Ibáñez, Queralt Jordano Montañez, Mariona Xercavins Valls, Javier Martinez-Lacasa, Pablo Velli, Roser Font.
Hospital de Navarra (Pamplona) —
Julio Sola Boneta, Javier Uriz, Jesús Castiello, Jesús Reparaz, María Jesús Arraiza, Carmen Irigoyen, David Mozas.
Hospital Parc Taulí (Sabadell) —
Ferrán Segura, María José Amengual, Eva Penelo, Gemma Navarro, Montserrat Sala, Manuel Cervantes, Valentín Pineda.
Hospital Ramón y Cajal (Madrid) —
Santiago Moreno, José Luis Casado, Fernando Dronda, Ana Moreno, María Jesús Pérez Elías, Dolores López, Carolina Gutiérrez, Beatriz Hernández, María Pumares, Paloma Martí.
Hospital Reina Sofía (Murcia) —
Alfredo Cano Sánchez, Enrique Bernal Morell, Ángeles Muñoz Pérez.
Hospital San Cecilio (Granada) —
Federico García García, José Hernández Quero, Alejandro Peña Monje, Leopoldo Muñoz Medina, Jorge Parra Ruiz.
Centro Sanitario Sandoval (Madrid) —
Jorge Del Romero Guerrero, Carmen Rodríguez Martín, Teresa Puerta López, Juan Carlos Carrió Montiel, Cristina González.
Hospital Universitario Santiago de Compostela (Santiago de Compostela) —
Antonio Antela, Arturo Prieto, Elena Losada.
Hospital Son Dureta (Palma de Mallorca) —
Melchor Riera, Javier Murillas, Maria Peñaranda, Maria Leyes, Mª Angels Ribas, Antoni Campins, Concepcion Villalonga.
Hospital Universitario de Valme (Sevilla) —
Juan Antonio Pineda, Eva Recio Sánchez, Fernando Lozano de León, Juan Macías, José del Valle, Jesús Gómez-Mateos, Rosario Mata.
Hospital Virgen de la Victoria (Málaga) —
Jesús Santos González, Manuel Márquez Solero, Isabel Viciana Ramos, Rosario Palacios Muñoz.
Hospital Universitario Virgen del Rocío (Sevilla) —
Pompeyo Viciana, Manuel Leal, Luis Fernando López-Cortés, Mónica Trastoy.
References
- 1.Brookmeyer R. Statistical problems in epidemiologic studies of the natural history of disease. Environmental Health Perspectives. 1990;87:43–49. doi: 10.1289/ehp.908743. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brookmeyer R, Gail MH. Biases in prevalent cohorts. Biometrics. 1987;43(4):739–749. [PubMed] [Google Scholar]
- 3.Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. American Journal of Epidemiology. 1987;126(1):14–24. doi: 10.1093/oxfordjournals.aje.a114646. [DOI] [PubMed] [Google Scholar]
- 4.The UK Collaborative HIV Cohort (UK CHIC) Steering Committee. Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS. 2010;24(5):723–727. doi: 10.1097/QAD.0b013e328333fa0f. [DOI] [PubMed] [Google Scholar]
- 5.Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine. 2008;9(6):397–405. doi: 10.1111/j.1468-1293.2008.00566.x. [DOI] [PubMed] [Google Scholar]
- 6.Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Medicine. 2011;12(1):61–64. doi: 10.1111/j.1468-1293.2010.00857.x. [DOI] [PubMed] [Google Scholar]
- 7.Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antiviral Therapy. 2010;15, supplement 1:31–35. doi: 10.3851/IMP1525. [DOI] [PubMed] [Google Scholar]
- 8.Antinori A, Johnson M, Moreno S, Rockstroh JK, Yazdanpanah Y. Introduction to late presentation for HIV treatment in Europe. Antiviral Therapy. 2010;15, supplement 1:1–2. doi: 10.3851/IMP1521. [DOI] [PubMed] [Google Scholar]
- 9.Brancato G, Pezzotti P, Rapiti E, et al. Multiple imputation method for estimating incidence of HIV infection. International Journal of Epidemiology. 1997;26(5):1107–1114. doi: 10.1093/ije/26.5.1107. [DOI] [PubMed] [Google Scholar]
- 10.Muñoz A, Carey V, Taylor JMG, et al. Estimation of time since exposure for a prevalent cohort. Statistics in Medicine. 1992;11(7):939–952. doi: 10.1002/sim.4780110711. [DOI] [PubMed] [Google Scholar]
- 11.Pérez-Hoyos S, Ferreros I, Hurtado I, Del Amo J, Hernández-Aguado I. Imputation of the begining of follow up in longitudinal studies applied to the HIV infection. Revista Espanola de Salud Publica. 2004;78(2):215–227. doi: 10.1590/s1135-57272004000200008. [DOI] [PubMed] [Google Scholar]
- 12.Teira Cobo R, Suárez Lozano I, Santamaría Jáuregui JM, et al. Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997–2002] Gaceta Sanitaria. 2007;21(1):66–69. doi: 10.1157/13099123. [DOI] [PubMed] [Google Scholar]
- 13.Girardi E, Aloisi MS, Arici C, et al. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. Journal of Acquired Immune Deficiency Syndromes. 2004;36(4):951–959. doi: 10.1097/00126334-200408010-00009. [DOI] [PubMed] [Google Scholar]
- 14.Pugliese P, Cuzin L, Cabié A, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Medicine. 2009;10(8):504–511. doi: 10.1111/j.1468-1293.2009.00719.x. [DOI] [PubMed] [Google Scholar]
- 15.JaEn A, Casabona J, Esteve A, et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS project. Medicina Clinica. 2005;124(14):525–531. doi: 10.1157/13073938. [DOI] [PubMed] [Google Scholar]
- 16.Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact of mortality. Current HIV Research. 2009;7(2):224–230. doi: 10.2174/157016209787581535. [DOI] [PubMed] [Google Scholar]
- 17.Castilla J, Sobrino P, de La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS. 2002;16(14):1945–1951. doi: 10.1097/00002030-200209270-00012. [DOI] [PubMed] [Google Scholar]
- 18.Castilla J, Lorenzo JM, Izquierdo A, et al. Characteristics and trends of newly diagnosed HIV-infections, 2000–2004. Gaceta Sanitaria. 2006;20(6):442–448. doi: 10.1157/13096525. [DOI] [PubMed] [Google Scholar]
- 19.Sobrino-Vegas P, Gutiérrez F, Berenguer J, et al. The cohort of the spanish hiv research network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up. doi: 10.1016/j.eimc.2011.06.002. Enfermedades Infecciosas y Microbiología Clínica. In press. [DOI] [PubMed] [Google Scholar]
- 20.Lodi S, Phillips A, Touloumi G, et al. Time from HIV seroconversion to reaching CD4 thresholds <200 , <350 and <500 cells/mm3, assessment of need following changes in treatment guidelines. Clinical Infectious Diseases. 2011;53(8):817–825. doi: 10.1093/cid/cir494. [DOI] [PubMed] [Google Scholar]
- 21.Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56(2):645–646. doi: 10.1111/j.0006-341x.2000.00645.x. [DOI] [PubMed] [Google Scholar]
- 22.R Development Core Team. Tech. Rep. ISBN 3-900051-07-0. Vienna, Austria: R Foundation for Statistical Computing; R: A language and environment for statistical computing. 2011, http://www.R-project.org. [Google Scholar]
- 23.HIV Surveillance in Spain. Assessing new HIV cases in Spain from autonomous communities notification systems: 2003–2009 period. 2011, http://www.isciii.es/htdocs/centros/epidemiologia/epi_nuevos_diagnosticos.jsp.
- 24.Geskus RB. On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion. Statistics in Medicine. 2000;19(13):1753–1769. doi: 10.1002/1097-0258(20000715)19:13<1753::aid-sim487>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- 25.Taffé P, May M, Bachmann S, et al. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Statistics in Medicine. 2008;27(23):4835–4853. doi: 10.1002/sim.3294. [DOI] [PubMed] [Google Scholar]
- 26.Prins M, Roy Robertson J, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS. 1999;13(17):2361–2364. doi: 10.1097/00002030-199912030-00007. [DOI] [PubMed] [Google Scholar]